TY - JOUR
T1 - Ablative therapy for movement disorders
T2 - Thalamotomy for Parkinson's disease
AU - Perry, V. L.
AU - Lenz, F. A.
PY - 1998
Y1 - 1998
N2 - Thalamotomy for Parkinson's disease is a well-established procedure that has been in use for more than 40 years. Technologic advances, such as computerized and magnetic resonance imaging, and refinement of stereotactic techniques have increased the safety and efficacy of this procedure. Current studies reveal good results in 70% to 90% of patients. Reported transient neurologic deficits occur in up to 60% of patients undergoing this procedure, although the highest permanent complication rates have decreased to around 10% to 20%. These data suggest the safety and efficacy of thalamotomy as a primary therapeutic option for selected patients with parkinsonian tremor.
AB - Thalamotomy for Parkinson's disease is a well-established procedure that has been in use for more than 40 years. Technologic advances, such as computerized and magnetic resonance imaging, and refinement of stereotactic techniques have increased the safety and efficacy of this procedure. Current studies reveal good results in 70% to 90% of patients. Reported transient neurologic deficits occur in up to 60% of patients undergoing this procedure, although the highest permanent complication rates have decreased to around 10% to 20%. These data suggest the safety and efficacy of thalamotomy as a primary therapeutic option for selected patients with parkinsonian tremor.
UR - http://www.scopus.com/inward/record.url?scp=0031939985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031939985&partnerID=8YFLogxK
U2 - 10.1016/s1042-3680(18)30267-5
DO - 10.1016/s1042-3680(18)30267-5
M3 - Review article
C2 - 9495894
AN - SCOPUS:0031939985
VL - 9
SP - 317
EP - 323
JO - Neurosurgery Clinics of North America
JF - Neurosurgery Clinics of North America
SN - 1042-3680
IS - 2
ER -